rred 
by IBA in the compliance effort to renew a license 
to sell medical devices in Europe in line with the 
new European Medical Device Regulation. The 
costs incurred are mainly internal staff costs and 
are considered as development as all criteria 
under IAS 38 are met. The project is still in 
progress and the related costs are capitalised in 
the heading Other for EUR 5.7 million, out of 
which EUR 3.7 million were incurred this year. Finally, further investments were made in 
software development.